Brief Reports

Percutaneous Closure of Pseudoaneurysm of the Mitral-Aortic Intervalvular Fibrosa

Santiago Jiménez Valero, a Eulogio García, b Ángel González Pinto, c and Juan L. Delcán a

aUnidad de Hemodinámica y Cardiología Intervencionista, Hospital de Madrid Montepríncipe, Madrid, Spain.
bServicio de Cardiología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
cServicio de Cirugía Cardíaca, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Pseudoaneurysm of the mitral-aortic intervalvular fibrosa is an uncommon event, which is usually secondary to endocarditis of the aortic valve. Its clinical evolution is variable and potentially serious complications can occur. Therefore, surgical treatment is usually recommended. To the best of our knowledge, this is the first description of percutaneous treatment of this disease.

Key words: Intervalvular mitral-aortic fibrosa. Pseudoaneurysm. Interventional cardiology.

INTRODUCTION

The mitral-aortic fibrosa is a thin layer of fibrous tissue that separates the posterior portion of the aortic root from the base of the anterior mitral leaflet. Its posterior and lateral limit is defined by the left atrium, the inferior limit by the left ventricular outflow tract (LVOT), and the upper limit by the pericardium.1-4 Pseudoaneurysm of the mitral-aortic fibrosa (PMAF) or intervalvular fibrosa is an uncommon condition, consisting of a pulsatile cavity in the mitral-aortic junction communicating with the left ventricular outflow tract. The most frequent cause is aortic valve endocarditis, particularly in prosthetic valves.1-2 We present a case of asymptomatic PMAF developing late following aortic valve replacement surgery and treated by percutaneous closure.

CLINICAL CASE

A 69-year-old woman with a history of hypertension presented syncope on exercise. She was diagnosed with severe degenerative aortic stenosis, with a peak gradient of 130 mm Hg and a mean of 81 mm Hg. The mitral valve and ventricular function were normal and coronary angiography showed normal coronary vasculature. The patient underwent surgery with implantation of a Toronto SPV® size 23 aortic stentless bioprosthesis; there were no postoperative complications. Follow-up echocardiography showed normal coronary vasculature. Seven years following the procedure the patient remained asymptomatic. On transthoracic echocardiography (TTE) the aortic valve and ventricular function were normal and coronary angiography showed normal coronary vasculature. The patient underwent surgery with implantation of a Toronto SPV® size 23 aortic stentless bioprosthesis; there were no postoperative complications. Follow-up echocardiography showed no relevant abnormalities.

Correspondence: Dr. S. Jiménez Valero.
Unidad de Hemodinámica. Hospital de Madrid Montepríncipe.
E-mail: sjvcardio@yahoo.es

Received January 28, 2005.
Accepted for publication April 29, 2005.

Jiménez Valero S, et al. Percutaneous Closure of Pseudoaneurysm of the Mitral-Aortic Intervalvular Fibrosa

interior of the PMAF, and with the help of a multipurpose catheter, was exchanged for an Amplatzer® wire. A 12-mm Amplatzer® Muscular VSD Occluder device (AGA Medical, USA) was advanced over the wire and placed in the neck of the aneurysm (the diameter of the device chosen was slightly larger than the neck). Positioning of the device was confirmed by ventriculography in two views (RAO 30° and LAO 45°) and by TEE, to assure that there was no interference with the aortic bioprosthesis or mitral valve function. After deployment of the device, TEE and angiography showed absence of flow to the cavity. Transesophageal echocardiography performed at 6 months confirmed these findings and the patient remained asymptomatic at 1 year of follow-up.

DISCUSSION

Pseudoaneurysm of the mitral-aortic fibrosa usually occurs in patients with a history of aortic valve replacement due to endocarditis. It is more commonly associated with prosthetic valves, probably due to abscess formation at the ring, which fistulizes toward the outflow tract.1-4 There are also reports of cases, such as the one described, occurring after aortic valve surgery for processes other than endocarditis.5 Partial dehiscence of an aortic prosthesis can contribute to the formation of PMAF.3 Sometimes, as in our case, the pseudoaneurysm is diagnosed years after the surgical intervention.4-6 Isolated cases secondary to chest trauma have also been described.7

The clinical spectrum varies from asymptomatic cases to cardiac tamponade due to rupture of the PMAF toward the pericardial cavity.8 Progressive enlargement of the pseudoaneurysm can produce angina due to compression of the coronary arteries,6,9,10 and fistula may form toward the anterior chest wall.4 Heart failure is another manifestation, occurring when the pseudoaneurysm communicates with the ascending aorta or left ventricle; the clinical picture is similar to that of aortic or mitral regurgitation, respectively. Severe mitral regurgitation caused by displacement of the anterior mitral leaflet has been described.11 Another manifestation is stroke,
occurring as a consequence of embolization of the thrombotic material within the PMAF.\textsuperscript{12}

The recommended treatment for PMAF is surgery even in asymptomatic patients,\textsuperscript{2} in order to prevent the development of complications. Resection and repair of the defect\textsuperscript{4,10} can be done with or without aortic valve replacement\textsuperscript{5,6,10} or homograft replacement of the aortic root.\textsuperscript{2} When there is coronary involvement, a bypass may be necessary.\textsuperscript{6,8} Surgery for this condition is technically complex and patients often have a background of prior surgery; hence the associated morbidity and mortality is not negligible.

To the best of our knowledge, the case presented is the first description of percutaneous treatment for PMAF. The rationale for this approach was that isolation of the cavity from the LVOT would prevent enlargement of the pseudoaneurysm and potential complications. We conclude that this is a viable technique that can be performed safely, yields good results at middle term, and may be an alternative to surgical treatment.

REFERENCES


